Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4575-4580

  Dunn, D T ^a   Goodall, R L ^a   Munderi, P ^b   Kityo, C ^c   Ranopa, M ^a   Bacheler, L ^d   Van Houtte, M ^d   Gilks, C ^e   Kaleebu, P ^b   Pillay, D ^f  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c JOINT CLINICAL RESEARCH CENTRE   (Uganda)

^d Virco BVBA   (Belgium)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; HUMAN IMMUNODEFICIENCY VIRUS 1 RNA; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIROLOGICAL RESIDUAL ACTIVITY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; NEVIRAPINE; RNA, VIRAL; VIRAL LOAD; ZIDOVUDINE;

EID: 80052827562     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00580-11     Document Type: Article

References (31)

1. Ait-Khaled, M., et al. 2002. M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine. CNA3002 International Study Team. AIDS 16:1686-1689. (Pubitemid 34921117)
2. Brun-Vézinet, F., et al. 1997. HIV-1 viral load, phenotype, and resistance in a subset of drug-naive participants from the Delta trial. The National Virology Groups. Delta Virology Working Group and Coordinating Committee. Lancet 350:983-990.
3. Brun-Vézinet, F., et al. 2004. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir. Ther. 9:465-478.
4. Campbell, T. B., et al. 2005. Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection. Clin. Infect. Dis. 41:236-242.
5. Cane, P., H. Green, E. Fearnhill, D. T. Dunn, and the UK Collaborative Group on HIV Drug Resistance. 2007. Identification of accessory mutations associated with high level resistance in HIV-1 reverse transcriptase. AIDS 21:447-455.
6. Castagna, A., et al. 2006. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS 20:795-803. (Pubitemid 43731560)
7. DART Trial Team. 2008. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/μl. AIDS 22:237-247.
8. DART Trial Team. 2008. Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). Trop. Med. Int. Health 13:6-16.
9. DART Trial Team. 2010. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 375:123-131.
10. Deeks, S. G., et al. 2005. Interruption of treatment with individual therapeutic drug classes in adults with multidrug-resistant HIV-1 infection. J. Infect. Dis. 192:1537-1544.
11. Eron, J. J., et al. 1995. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N. Engl. J. Med. 333:1662-1669.
12. Eron, J. J., Jr., et al. 2004. Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation. J. Acquir. Immune Defic. Syndr. 37:1581-1583.
13. Fiscus, S. A., et al. 1998. Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. AIDS Clinical Trials Group Protocol 175 Team. J. Infect. Dis. 177:625-633.
14. Frost, C. 2000. Correcting for regression dilution bias: comparison of methods for a single predictor variable. J. Royal Stat. Soc. A 163:173-189.
15. Gilks, C. F., et al. 2006. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368:505-510. (Pubitemid 44142772)
16. Hertogs, K., et al. 1998. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob. Agents Chemother. 42:269-276.
17. Hirsch, M. S., et al. 2008. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 47:266-285.
18. Johnson, V. A., et al. 2009. Update of the drug resistance mutations in HIV-1: December 2009. Top. HIV Med. 17:138-145.
19. Lanier, E. R., et al. 2004. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir. Ther. 9:37-45.
20. Ledergerber, B., et al. 2004. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet 364:51-62.
21. Little, S. J., et al. 2008. Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection. J. Virol. 82:5510-5518. (Pubitemid 351705258)
22. Munderi, P., et al. 2010. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med. 11:334-344.
23. Ndembi, N., et al. 2010. Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus nevirapine and zidovudine-lamivudine plus abacavir. J. Infect. Dis. 201:106-113.
24. Quattro Steering Committee. 2002. Observations of HIV-1 genotypic drug resistance in a trial of four reverse transcriptase inhibitors (Quattro Trial). Antivir. Ther. 7:11-20.
25. Rong, L., M. A. Gilchrist, Z. Feng, and A. S. Perelson. 2007. Modeling within-host HIV-1 dynamics and the evolution of drug resistance: trade-offs between viral enzyme function and drug susceptibility. J. Theor. Biol. 247:804-818.
26. Royston, P., and D. G. Altman. 1994. Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling (with discussion). Appl. Stat. 43:429-467.
27. Schooley, R. T., et al. 1996. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. 1. J. Infect. Dis. 173:1354-1366. (Pubitemid 26286794)
28. Wilson, D., M. Law, A. Grulich, D. Cooper, and J. Kaldor. 2008. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 372:314-320. (Pubitemid 352020440)
29. Winters, B., et al. 2008. Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data. J. Acquir. Immune Defic. Syndr. 48:26-34.
30. Winters, B., et al. 2009. Clinical cut-offs for HIV-1 phenotypic resistance estimates: update based on recent pivotal clinical trial data and a revised approach to viral mixtures. J. Virol. Methods 162:101-108.
31. Wirden, M., et al. 2003. Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs. J. Clin. Microbiol. 41:2713-2715.